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We present a European Union/European Economic 
Area-wide overview of the changes in consumption of 
antibacterials for systemic use (ATC J01) in the com-
munity between 2019 and 2020 as reported to the 
European Surveillance of Antimicrobial Consumption 
Network. Overall antibiotic consumption decreased 
by 18.3% between 2019 and 2020, the largest annual 
decrease in the network’s two-decade history. We 
observed a strong association between the level of 
community antibiotic consumption in 2019 and the 
size of the decrease between 2019 and 2020. 
The ongoing coronavirus disease (COVID-19) pandemic 
has since its start in early 2020 affected societies 
worldwide. In addition to the direct COVID-19-related 
morbidity and mortality, secondary effects on general 
communicable disease epidemiology and healthcare 
system delivery have also been reported [1,2].
Here, we present a European Union (EU)/European 
Economic Area (EEA)-wide overview of the changes in 
antibiotic consumption in the community in 2020 com-
pared with previous years. We analysed the consump-
tion of antibacterials for systemic use (ATC group J01), 
and focused on the community, i.e. the primary care 
sector, as this is where the changes between 2019 and 
2020 were the largest at EU/EEA level and the most 
consistent among EU/EEA countries [3]. 
EU/EEA population-weighted mean 
antibiotic consumption
Our analyses are based on data reported to the 
European Surveillance of Antimicrobial Consumption 
Network (ESAC-Net), collected using a methodology 
described elsewhere [4] and expressed as defined 
daily doses (DDD) per 1,000 inhabitants per day, using 
the Anatomical Therapeutic Chemical (ATC) Index for 
2021 [5]. Statistical analyses were performed with 
Stata version 16.0 [6]. The EU/EEA population-weighted 
mean is based on data from 29 countries. For 27 of 
these countries, separate data for the community sec-
tor were available and for two countries, data were 
imputed based on total consumption. The difference 
in antibiotic consumption between 2019 and 2020 
was considerably larger than in previous years. While 
the EU/EEA population-weighted mean annual change 
in the consumption of antibacterials for systemic use 
(ATC group J01) during the period 2016 and 2019 was 
−0.34 DDD/1,000 inhabitants/day, representing a 1.8% 
annual decrease (median: −0.44 DDD/1,000 inhabit-
ants/day or a 2.3% annual decrease), it decreased by 
−3.35 DDD/1000 inhabitants/day between 2019 and 
2020, representing a 18.3% decrease (Figure 1).
For individual groups of antibiotics, the largest 
decrease in terms of DDD/1,000 inhabitants/day 
between 2019 and 2020 was observed for penicillins 
(ATC group J01C; −1.88 DDD/1000 inhabitants/day; 
−22.7%), followed by other beta-lactam antibacteri-
als (J01D; −0.58 DDD/1,000 inhabitants/day; −25.5%), 
macrolides, lincosamides and streptogramins (J01F; 
−0.50 DDD/1,000 inhabitants/day; −17.2%), quinolo-
nes (J01M; −0.20 DDD/1,000 inhabitants/day; −14.6%), 
tetracyclines (J01A; −0.12 DDD/1,000 inhabitants/day; 
−6.9%), sulfonamides and trimethoprim (J01E; −0.04 
DDD/1,000 inhabitants/day; −6.8%), other antibacteri-
als (J01X; −0.02 DDD/1,000 inhabitants/day; −2.2%), 
and ATC groups J01B, J01G and J01R combined ; −0.01 
DDD/1,000 inhabitants/day; −9.3%) (Figure 2).
Country-level antibiotic consumption
Twenty-seven countries reported separate data on 
community consumption for 2019 and 2020. Of these, 
26 reported a decrease in community consumption of 
antibacterials for systemic use in 2020 compared with 
2019, while one country (Bulgaria) reported an increase 
during the same period (Figure 2).
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Among the 26 countries reporting a decrease, there 
was a positive association between the level of antibi-
otic consumption in 2019 and the size of the decrease in 
antibiotic consumption between 2019 and 2020 meas-
ured in DDD/1,000 inhabitants/day (Pearson’s correla-
tion coefficient: 0.70, p value 0.0001); the decrease 
was proportionally larger in countries with high com-
munity antibiotic consumption than in countries with 
low antibiotic consumption (Figure 3).
For individual groups of antibiotics, there were various 
patterns of change in the 26 countries that reported a 
decrease overall. All 26 countries reported a decrease 
in the consumption of penicillins (ATC J01C) between 
2019 and 2020, which corresponded to the largest 
reduction when expressed in DDD/1,000 inhabit-
ants/day. A majority of countries also reported large 
reductions in the consumption of other beta-lactams, 
which includes cephalosporins (J01D), and of mac-
rolides, lincosamides and streptogramins (J01F) (Figure 
2). Only two countries (Bulgaria and Romania) reported 
an increase in the consumption of macrolides, lincosa-
mides and streptogramins (J01F), and the increase in 
these countries (+1.71 DDD/1,000 inhabitants/day or 
a +42.6% increase, and +1.44 DDD/1,000 inhabitants/
day or a + 46.7% increase, respectively) was the larg-
est observed for any antibiotic group and country. For 
both countries, the increase in this group resulted 
from an increase in the consumption of azithromy-
cin (J01FA10; +1.61 DDD/1,000 inhabitants/day or 
a +105.2% increase, and +1.92 DDD/1,000 inhabitants/
day or a +178.2% increase, respectively). Five other 
countries also reported increased consumption of 
azithromycin during the same period, but at a much 
Figure 1
Consumption of antibacterials for systemic use (ATC group J01) in the community, population-weighted mean, by ATC 
group, 29 EU/EEA countries, 2016–2020
ATC: anatomical therapeutic chemical index; DDD: defined daily doses; EEA: European Economic Area; EU: European Union.
The population-weighted mean is based on antimicrobial consumption data reported by 29 EU/EEA countries (Austria, Belgium, Bulgaria, 
Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, 
Malta, the Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain and Sweden). Cyprus and Czechia only reported 
total care data (community and hospital consumption combined), and community consumption was imputed by assuming that community 
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Consumption of antibacterials for systemic use (ATC group J01) in the community, EU/EEA countries, change between 
2019 and 2020
ATC: anatomical therapeutic chemical index; DDD: defined daily doses; ECDC: European Centre for Disease Prevention and Control; EEA: 
European Economic Area; EU: European Union; TESSy: The European Surveillance System.
a Luxembourg changed the data process between 2019 and 2020, which could impact comparability between the years.
Individual country analyses were available for 27 countries. EU/EEA refers to the corresponding population-weighted mean consumption 
based on antimicrobial consumption data reported by 29 EU/EEA countries (Austria, Belgium, Bulgaria, Croatia, Cyprus, Czechia, Denmark, 
Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Norway, 
Poland, Portugal, Romania, Slovakia, Slovenia, Spain and Sweden). Cyprus and Czechia only reported total care data (community and hospital 
consumption combined),and their contribution to the EU/EEA population-weighted mean community consumption was imputed by assuming 
that community consumption contributed 90% of total care consumption Data extracted from ECDC TESSy on 7 September 2021.
Country 
Change in community consumption of antibacterials for systemic use between 2019 and 2020 by group and by country





























Austria −0.038 (−12.1) −0.848 (−20.2) −0.317 (−24.9) +0.003 (+1.27) −0.619 (−30.1) −0.161 (−22.1) −0.064 (−17.7) −0.001 (−6.1) −2.046 (−22.3) 
Belgium −0.233 (−12.5) −2.824 (−28.8) −0.402 (−33.5) +0.008 (+3.74) −0.857 (−24.5) −0.112 (−19.6) −0.100 (−3.8) −0.005 (−19.7) −4.524 (−22.9) 
Bulgaria +0.505 (+30.0) −0.659 (−12.3) −0.305 (−7.1) −0.135 (−17.4) +1.708 (+42.6) +0.581 (+21.0) −0.002 (−15.2) −0.003 (−1.8) +1.689 (+8.9) 
Croatia −0.138 (−14.9) −1.727 (−21.9) −0.463 (−18.1) −0.054 (−10.9) −0.350 (−12.5) −0.142 (−10.4) −0.012 (−1.3) −0.001 (−15.8) −2.886 (−17.0) 
Denmark +0.214 (+14.5) −0.848 (−9.5) +0.001 (+0.4) −0.038 (−6.6) −0.236 (−16.5) −0.040 (−10.7) +0.031 (+5.1) −0.009 (−54.0) −0.927 (−6.9) 
Estonia +0.002 (0.13) −0.571 (−15.2) −0.169 (−14.2) −0.122 (−29.5) −0.531 (−22.8) +0.071 (+10.9) −0.109 (−19.5) −0.002 (−29.5) −1.431 (−14.0) 
Finland −0.611 (−20.5) −1.256 (−29.0) −0.272 (−15.3) −0.114 (−10.6) −0.194 (−30.9) −0.085 (−17.9) −0.073 (−5.6) −0.001 (−5.9) −2.604 (−20.7) 
France −0.294 (−9.2) −3.252 (−24.4) −0.399 (−31.2) +0.281 (+6.6) −0.475 (−16.9) −0.118 (−9.8) −0.075 (−16.5) −0.058 (−9.5) −4.643 (−19.9) 
Germany −0.110 (−7.0) −0.905 (−22.9) −0.685 (−29.0) −0.069 (−13.7) −0.510 (−28.0) −0.145 (−22.9) 0.002 (0.4) −<0.001 (−3.2) −2.422 (−21.3) 
Greece −0.054 (−1.8) −2.263 (−20.7) −1.831 (−24.1) +0.115 (+35.4) −1.541 (−23.4) −0.426 (−14.0) −0.023 (−2.8) −0.010 (−16.5) −6.033 (−18.6) 
Hungary +0.038 (+3.3) −1.456 (−31.5) −0.681 (−33.1) −0.060 (−13.5) −0.551 (−19.8) −0.517 (−26.9) −0.007 (−2.5) 0.001 (11.1) −3.233 (−24.4) 
Iceland −0.447 (−8.7) −1.484 (−17.5) −0.052 (−9.6) −0.028 (−5.2) −0.268 (−19.7) −0.078 (−13.4) −0.152 (−13.5) +0.008 (+87.4) −2.500 (−14.1) 
Ireland −0.017 (−0.6) −2.687 (−26.8) −0.210 (−18.0) +0.043 (+4.3) −0.932 (−24.1) −0.129 (−23.4) +0.004 (+0.3) −0.004 (−19.1) −3.932 (−18.7) 
Italy +0.025 (+4.5) −1.862 (−20.2) −0.590 (−26.0) −0.054 (−6.2) −0.491 (−12.1) −0.321 (−16.1) +0.010  (+1.4) −0.017 (−21.8) −3.299 (−16.7) 
Latvia −0.012 (−0.5) −1.058 (−22.8) −0.209 (−33.8) +0.029 (+3.8) −0.480 (−22.5) −0.080 (−9.3) +0.040 (+5.4) +0.001 (+4.1) −1.768 (−14.7) 
Lithuania +0.067 (+4.7) −1.413 (−22.4) −0.164 (−12.2) +0.003 (+0.6) −0.433 (−20.5) −0.096 (−11.7) +0.125 (+9.7) +0.001 (+4.2) −1.910 (−13.8) 
Luxembourga −0.460 (−22.5) −2.284 (−27.4) −0.993 (−36.2) +0.015 (+5.0) −0.814 (−24.8) −0.309 (−19.6) −0.059 (−4.0) −0.008 (−44.1) −4.911 (−24.9) 
Malta +0.340 (+19.5) −1.583 (−23.5) −0.851 (−29.8) −0.107 (−26.1) −1.793 (−42.3) −0.527 (−27.9) +0.291 (+53.0) −0.102 (−36.5) −4.331 (−23.1) 
Netherlands −0.287 (−15.7) −0.435 (−15.4) −0.001 (−2.1) −0.005 (−1.2) −0.089 (−6.1) −0.032 (−4.8) −0.056 (−4.0) −0.001 (−4.1) −0.905 (−10.4) 
Norway −0.227 (−8.4) −0.912 (−16.0) −0.003 (−5.3) −0.019 (−2.7) −0.219 (−25.1) −0.038 (−13.8) +0.566 (+17.3) −0.001 (−10.8) −0.854 (−6.3) 
Poland −0.403 (−18.7) −1.980 (−30.9) −1.189 (−33.8) −0.104 (−19.8) −1.155 (−29.5) −0.205 (−15.2) −0.039 (−0.9) −0.006 (−24.6) −5.081 (−22.9) 
Portugal −0.048 (−5.5) −2.384 (−26.3) −0.289 (−17.6) −0.022 (−5.8) −1.097 (−35.1) −0.333 (−21.6) −0.016 (−1.3) −<0.001 (−5.3) −4.188 (−23.4) 
Romania +0.142 (+16.4) −0.868 (−7.7) −0.719 (−15.7) −0.103 (−12.5) +1.442 (+46.7) −0.159 (−5.1) −0.065 (−35.8) +0.043 (+83.6) −0.288 (−1.2) 
Slovakia −0.027 (−1.6) −1.576 (−32.5) −1.559 (−32.1) −0.044 (−9.7) −1.280 (−28.0) −0.330 (−22.5) 0.002 (3.0) +<0.001 (+1.4) −4.813 (−26.8) 
Slovenia −0.012 (−2.2) −1.989 (−29.7) +0.017 (+4.4) −0.092 (−14.7) −0.399 (−23.0) −0.151 (−15.2) −0.021 (−4.2) −0.002 (−20.0) −2.649 (−23.0) 
Spain −0.039 (−2.6) −3.254 (−24.7) −0.439 (−18.6) −0.008 (−1.8) −0.715 (−25.4) −0.513 (−22.3) −0.029 (−5.8) −0.022 (−11.4) −5.018 (−21.6) 
Sweden −0.216 (−10.1) −1.010 (−18.4) −0.008 (−12.8) −0.015 (−5.4) −0.022 (−4.2) −0.067 (−12.0) −0.073 (−5.7) +<0.001 (+6.0) −1.410 (−13.7) 
EU/EEA −0.12 (−6.9) −1.88 (−22.7) −0.58  (−25.5) −0.04 (−6.8) −0.50 (−17.2) −0.20 (−14.6) −0.02 (−2.2) −0.01  (−9.3) −3.35  (−18.3) 
Decreasing DDD/1,000 inhabitants/day Increasing  DDD/1,000 inhabitants/day 
  First quartile (p0;p25)   First quartile (p0;p25) 
  Second quartile (p25;p50)   Second quartile (p25;p50) 
  Third quartile (p50;p75)   Third quartile (p50;p75) 
Fourth quartile  (p75;p100 ) 
  Fourth quartile (p75;p100 ) 
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smaller magnitude (range: +0.01 to +0.26 DDD/1,000 
inhabitants/day) and with an overall decrease in the 
consumption for the ATC group J01F.
Discussion
The unprecedented decrease in community antibiotic 
consumption noted in the EU/EEA between 2019 and 
2020 is the largest in ESAC-Net’s two-decade long 
antimicrobial consumption surveillance history, and 
one example of the far-reaching consequences of the 
COVID-19 pandemic. Although similar changes in com-
munity antibiotic consumption have been described 
at the local and national levels [7-10], this is the first 
report showing a substantial decrease across nearly all 
EU/EEA countries.
Because patient-level data are lacking in ESAC-Net, 
we could not assess whether the observed decrease 
reflects concomitant changes in disease transmis-
sion, healthcare utilisation patterns or prescription 
practices. Nevertheless, the large decrease noted for 
antibiotics commonly used to treat respiratory tract 
infections, e.g. penicillins and other beta-lactam anti-
bacterials, is in line with the reported low incidence 
of non-COVID-19-related respiratory tract infections in 
the EU/EEA in 2020 [1,11]. This has been attributed to 
the non-pharmaceutical interventions put in place as a 
response to the pandemic, including physical distanc-
ing, respiratory etiquette, face masks and promotion of 
hand hygiene [12]. In addition, the decrease in commu-
nity antibiotic consumption may have resulted from a 
decrease in the number of primary care consultations 
that were due to community lockdowns and reduced 
access to primary care during the period [2,8,9], which 
would most probably mainly result in fewer antibiotic 
prescriptions for mild and self-limiting infections. 
However, there was a more than 20-fold inter-country 
variation in the size of the decrease in community anti-
biotic consumption between 2019 and 2020. In gen-
eral, countries with comparatively high community 
antibiotic consumption and showing a poor perfor-
mance for quality indicators for antibiotic consumption 
in the community [13], reported the largest decreases 
between 2019 and 2020.
Inversely, two countries with high community antibi-
otic consumption reported either an increase (Bulgaria) 
or a comparatively small decrease (Romania) between 
2019 and 2020. This was mainly explained by a large 
increase in the community consumption of macrolides, 
and specifically azithromycin. Azithromycin has been 
postulated to have antiviral and anti-inflammatory 
activity and has been studied for the treatment of 
COVID-19, however, multiple studies did not identify 
any clinical benefit [14].
It cannot be excluded that the ongoing COVID-19 pan-
demic could have impacted the quality of the data. 
However, with the exception of Luxembourg that imple-
mented a change in data processing in 2020, we are 
not aware of any other changes in data sources or data 
collection processes between 2019 and 2020.
Evidence-based international guidelines have dis-
couraged antibiotics for prophylaxis or treatment in 
patients with mild or moderate COVID-19 infection 
without a suspicion of a bacterial co-infection [15,16], 
which would apply to most of the patients cared for in 
the community. Despite this, increased antibiotic con-
sumption and indications of overuse in the community 
have been reported during the COVID-19 pandemic 
[17]. Our study shows that, with a few exceptions, this 
seems to have been less of an issue in the EU/EEA. 
It could be speculated whether one of the reasons 
behind this favourable situation is the coordinated and 
EU-wide ongoing effort towards prudent use of antimi-
crobials, an essential component of the European One 
Health Action Plan against Antimicrobial Resistance 
(AMR) [18]. However, since this study focused on com-
munity antibiotic consumption, the interpretation can-
not be extrapolated to the hospital sector where the 
antibiotic consumption situation was more diverse [3].
Conclusion
The large changes in antibiotic consumption con-
comitant with the COVID-19 pandemic need to be fur-
ther evaluated, both in countries with high and low 
Figure 3
Scatter plot of consumption of antibacterials for systemic 
use (ATC group J01) in the community in 2019 vs change 
between 2019 and 2020, 27 EU/EEA countries
ATC: anatomical therapeutic chemical index; DDD: defined daily 
doses; ECDC: European Centre for Disease Prevention and Control; 
EEA: European Economic Area; EU: European Union; TESSy: The 
European Surveillance System.
Each dot represents a country. Included countries: Austria (AT), 
Belgium (BE), Bulgaria (BG), Croatia (HR), Denmark (DK), Estonia 
(EE), Finland (FI), France (FR), Germany (DE), Greece (EL), Hungary 
(HU), Iceland (IS), Ireland (IE), Italy (IT), Latvia (LV), Lithuania (LT), 
Luxembourg (LU), Malta (MT), the Netherlands (NL), Norway (NO), 
Poland (PL), Portugal (PT), Romania (RO), Slovakia (SK), Slovenia 
(SI), Spain (ES) and Sweden (SE). Countries which did not report 
data separately for the community sector, i.e. Cyprus and Czechia, 
were excluded from the analyses. Data extracted from ECDC TESSy 
on 7 September 2021.
Pearson’s correlation coefficient: 0.70, p value 0.0001. Sensitivity 
analyses excluding two outliers, Greece and Romania: Pearson’s 
correlation coefficient: 0.86, p value < 0.0001. Bulgaria was 
excluded from the correlation analysis as community consumption 
of antibacterials for systemic use consumption increased between 
2019 and 2020.
Country included in correlation analysis




antibiotic consumption, and areas of inappropriate 
antibiotic use need to be addressed within antimicro-
bial stewardship programmes in outpatient settings. It 
is still unclear whether this reduced community antibi-
otic consumption was sustained throughout 2021 and 
what implications it may have on antibiotic resistance. 
Robust surveillance systems will continue to be vital to 
monitor the situation.
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